Cover Image
市場調查報告書

UCB S.A.:產品平台分析

UCB S.A. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 243039
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
UCB S.A.:產品平台分析 UCB S.A. - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 91 Pages
簡介

UCB S.A.是開發各種疾病的醫藥品和解決方案的大生物醫藥品企業。

本報告提供UCB S.A.的治療藥開發平台的現狀及各開發階段比較分析,各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

UCB S.A.的基本資料

UCB S.A.概要

  • 主要資訊
  • 企業資料

UCB S.A.:R&D概要

  • 主要的治療範圍

UCB S.A.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

UCB S.A.:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請駁回/被撤消的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

UCB S.A.:藥物簡介

  • brivaracetam
  • certolizumab pegol
  • lacosamide
  • levetiracetam
  • rotigotine ER
  • bimekizumab
  • seletalisib
  • UCB-0942
  • UCB-7665
  • dapirolizumab pegol
  • UCB-4144
  • UCB-6673
  • 腫瘤、免疫學、發炎抗體
  • 糖尿病、代謝障礙脂肪酸結合蛋白質4阻礙單株抗體
  • 老年癡呆症TNF-α阻礙重組蛋白
  • 線維症用轉麩醯胺酸酶2阻礙抗體
  • 神經退行性疾病激酶阻礙小分子

UCB S.A.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

UCB S.A.:最近的開發平台趨勢

UCB S.A.:暫停中的計劃

UCB S.A.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • CDP-323
    • CDP-435
    • CDP-484
    • lacosamide
    • seletracetam
    • UCB-2892

UCB S.A.:企業發表

UCB S.A.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08030CDB

Summary

Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2016', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.
  • The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses UCB S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features UCB S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for UCB S.A.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding UCB S.A.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • UCB S.A. Snapshot
    • UCB S.A. Overview
    • Key Information
    • Key Facts
  • UCB S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • UCB S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • UCB S.A. - Pipeline Products Glance
    • UCB S.A. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • UCB S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • UCB S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • UCB S.A. - Drug Profiles
    • brivaracetam
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • certolizumab pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lacosamide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levetiracetam
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rotigotine ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bimekizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • seletalisib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UCB-0942
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UCB-7665
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dapirolizumab pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UCB-4144
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • UCB-6673
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Cancer, Immunology and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit Transglutaminase 2 for Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kinase for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • UCB S.A. - Pipeline Analysis
    • UCB S.A. - Pipeline Products by Target
    • UCB S.A. - Pipeline Products by Route of Administration
    • UCB S.A. - Pipeline Products by Molecule Type
    • UCB S.A. - Pipeline Products by Mechanism of Action
  • UCB S.A. - Recent Pipeline Updates
  • UCB S.A. - Dormant Projects
  • UCB S.A. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CDP-323
      • CDP-435
      • CDP-484
      • lacosamide
      • seletracetam
      • UCB-2892
  • UCB S.A. - Company Statement
  • UCB S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • UCB S.A., Key Information
  • UCB S.A., Key Facts
  • UCB S.A. - Pipeline by Indication, 2016
  • UCB S.A. - Pipeline by Stage of Development, 2016
  • UCB S.A. - Monotherapy Products in Pipeline, 2016
  • UCB S.A. - Partnered Products in Pipeline, 2016
  • UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016
  • UCB S.A. - Out-Licensed Products in Pipeline, 2016
  • UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • UCB S.A. - Pre-Registration, 2016
  • UCB S.A. - Phase III, 2016
  • UCB S.A. - Phase II, 2016
  • UCB S.A. - Phase I, 2016
  • UCB S.A. - Preclinical, 2016
  • UCB S.A. - Discovery, 2016
  • UCB S.A. - Pipeline by Target, 2016
  • UCB S.A. - Pipeline by Route of Administration, 2016
  • UCB S.A. - Pipeline by Molecule Type, 2016
  • UCB S.A. - Pipeline Products by Mechanism of Action, 2016
  • UCB S.A. - Recent Pipeline Updates, 2016
  • UCB S.A. - Dormant Developmental Projects,2016
  • UCB S.A. - Discontinued Pipeline Products, 2016
  • UCB S.A., Subsidiaries

List of Figures

  • UCB S.A. - Pipeline by Top 10 Indication, 2016
  • UCB S.A. - Pipeline by Stage of Development, 2016
  • UCB S.A. - Monotherapy Products in Pipeline, 2016
  • UCB S.A. - Partnered Products in Pipeline, 2016
  • UCB S.A. - Out-Licensed Products in Pipeline, 2016
  • UCB S.A. - Pipeline by Top 10 Target, 2016
  • UCB S.A. - Pipeline by Route of Administration, 2016
  • UCB S.A. - Pipeline by Molecule Type, 2016
  • UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top